Kleeberg, U R <br/><br/>
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Feb 2004 
 - 390-402 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0959-8049 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2003.07.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Disease-Free Survival<br/>Feasibility Studies<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Interferon-gamma--therapeutic use<br/>Lymphatic Metastasis<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Plant Extracts--therapeutic use<br/>Plant Proteins--therapeutic use<br/>Recombinant Proteins<br/>Risk Factors<br/>Skin Neoplasms--drug therapy<br/>Treatment Outcome